Big Law

Novo Nordisk Parent Company Refiles U.S. Application on Catalent Deal

The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent, a spokesperson said on Monday.

Novo Nordisk Foundation said last month it had agreed to buy Catalent to boost output of the weight-loss drug Wegovy. After the deal closes, it would sell three of Catalent’s fill-finish sites on to Novo Nordisk for $11 billion.

An application was submitted to U.S. anti-trust authorities on March 4. But “following informal discussions with the FTC staff”, the company withdraw and filed a new application on April 2, a Catalent SEC filing dated April 3 showed.

Read the source article at U.S. News

Back to top button